 On Tuesday, ImmunoGen Inc. NASDAQ:IMGN shares surged by nearly 30 after reporting positive mirvetuximab data in ovarian cancer. The company announced positive top-line data from the SORAYA trial, which measured the safety and efficacy of mirvetuximab soravtansine. 